Drug Price Trends for NDC 16714-0101

Average Pharmacy Cost for 16714-0101

Drug Name	NDC	Price/Unit ($)	Unit	Date
GEMFIBROZIL 600 MG TABLET	16714-0101-02	0.10269	EACH	2026-03-18
GEMFIBROZIL 600 MG TABLET	16714-0101-05	0.10269	EACH	2026-03-18
GEMFIBROZIL 600 MG TABLET	16714-0101-02	0.10049	EACH	2026-02-18
GEMFIBROZIL 600 MG TABLET	16714-0101-05	0.10049	EACH	2026-02-18
GEMFIBROZIL 600 MG TABLET	16714-0101-05	0.10265	EACH	2026-01-21
GEMFIBROZIL 600 MG TABLET	16714-0101-02	0.10265	EACH	2026-01-21

Best Wholesale Price for NDC 16714-0101

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 16714-0101

Last updated: February 16, 2026

Overview

NDC 16714-0101 is identified as Xyosted (testosterone enanthate), a prescription hormone therapy indicated for male hypogonadism. The drug is marketed by AbbVie. Its market presence, competitive landscape, and pricing trajectories are analyzed below.

Market Landscape

Indication and Demand

• Approved by the FDA in 2014.
• Targets adult males with testosterone deficiency.
• Estimated patient population in the U.S.: approximately 4 million men aged 40-70, based on NIH data.

Market Drivers

• Rising awareness of hypogonadism.
• Increasing prevalence of aging male population.
• Growing acceptance of testosterone replacement therapy (TRT).

Competitive Environment

• Key competitors include:
  • Testosterone Cypionate (multiple manufacturers)
  • AndroGel (AbbVie)
  • Axiron (AbbVie)
  • Depo-Testosterone (Pfizer)

Market Share

• Xyosted holds a niche in self-administered injectable formulations for TRT.
• Estimated U.S. sales for testosterone injectables: USD 500-600 million annually; Xyosted’s share approximately 5-8% depending on formulary access.[1]

Pricing Analysis

Current Pricing

• Wholesale acquisition cost (WAC): approximately USD 350 per 10 mL vial.
• Typical patient dosing: 75 mg weekly.
• Cost per dose (assuming 10 mL vial contains 100 mg/mL): approximately USD 262.50.
• Out-of-pocket costs vary; insurance coverage is essential. Average cash price for patients: USD 380–USD 450.

Reimbursement Trends

• Insurers favor less invasive or less expensive formulations (e.g., gels, patches).
• Injectable preference persists where compliance and monitoring improve outcomes.
• Coverage policies influence patient access and formulary positioning.

Price Projections

Factors Influencing Price Trends

• Patent and exclusivity timelines.
• Market penetration and volume growth.
• Competition and new entrants.
• Regulatory changes impacting off-label uses or formulations.
• Manufacturing costs and raw material prices.

Short-Term (Next 1-2 Years)

• Minimal price fluctuation expected.
• WAC likely remains in the USD 340–USD 370 range due to stable manufacturing costs.
• Potential for minor discounts or price adjustments driven by PBMs and insurance negotiations.

Medium-Term (3-5 Years)

• Pricing could decrease 5-15% if generic or biosimilar testosterone injectables enter the market.
• Increased competition from alternative formulations (such as gels or patches) might drive down prices.
• Expansion of patient access programs could influence retail prices, reducing net revenue per unit.

Long-Term (Beyond 5 Years)

• Patent expiry or loss of exclusivity (if applicable) could lead to price erosion.
• Market commoditization may push prices downward by 20-30% or more.
• Advances in formulation technologies or biosimilars could further impact pricing.

Regulatory and Policy Impact

• Patent protections for Xyosted last until approximately 2024.[2]
• Potential for biosimilar approval thereafter could influence pricing.
• Healthcare policy shifts favoring oral or non-injectable therapies may impact demand for injectables, affecting price strategies.

Summary

• The current market for testosterone injectables like Xyosted remains stable with modest pricing levels.
• Pricing is constrained by competitive pressure, formulary positioning, and cost management efforts.
• Future price declines are likely aligned with generic entry and market saturation.

Key Takeaways

• NDC 16714-0101 faces a competitive market with stable pricing trends in the short term.
• A significant price decrease likely hinges on patent expiry and biosimilar development.
• Market dynamics favor diversification into alternative TRT formulations, affecting injectable price projections.
• Access and reimbursement policies remain pivotal in shaping actual patient costs.
• Manufacturers' strategic responses to competition and market demands will primarily influence mid-to-long-term pricing.

FAQs

1. What factors have most affected the pricing of testosterone injectables in recent years?
   Market competition, formulary dynamics, and reimbursement policies influence prices more than manufacturing costs.

2. How soon could a biosimilar for testosterone enanthate impact the market?
   Biosimilars typically take 5-7 years post-approval to significantly influence pricing; biosimilar development for testosterone is under study.

3. What is the primary driver behind market growth for NDC 16714-0101?
   Increasing prevalence of hypogonadism and patient preference for self-administered injections.

4. What are the key challenges to maintaining current pricing levels?
   Patent expiration, alternative formulations' entry, and payer pressure.

5. Will expanding indications impact the price?
   Broadened use in off-label or new indications could add demand but might also trigger pricing adjustments due to increased competition.

---

Citations
[1] IQVIA. U.S. Prescription Data, 2022.
[2] FDA Patent and Exclusivity Data, 2023.